Cell-mediated immune competence in patients with prostatic carcinoma.
The immune competence of 65 patients with prostatic cancer was evaluated by 2 in vivo and 2 in vitro tests to study the contribution of host factors to the progress of the disease. Patients with benign prostatic hypertrophy served as controls. Our results indicate that the delayed skin hypersensitivity response to common microbial recall antigens (streptokinase/streptodornase, purified protein derivative, dermatophytin 0 and dermatophytin) is unaltered in advanced stages of malignancy. The ability to be sensitized by dinitrochlorobenzene declines significantly in patients with metastatic disease. Blastogenic response of peripheral blood lymphocytes to phytohemagglutinin stimulation is not depressed in late stages of malignancy, although in the circulating T cells per cent and absolute values are somewhat lower in patients with metastases. Herein we show that immune competence (measured by the 4 tests) of patients with prostatic carcinoma does not decrease markedly even in the late stages of the disease. Primary sensitization to dinitrochlorobenzene is the only test showing a decline in responsiveness related to the tumor stage.
D002277:Carcinoma / Q000276:immunology*; D004137:Dinitrochlorobenzene; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular; D007958:Leukocyte Count; D008214:Lymphocytes; D008297:Male; D009362:Neoplasm Metastasis; D010835:Phytohemagglutinins / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000276:immunology*; D012882:Skin Tests
D004137:Dinitrochlorobenzene; D010835:Phytohemagglutinins